Anthony E. Altig


Mr. Altig has been a director since 2012. From 2008 to December 2017, he was the Chief Financial Officer of Biotix Holdings, a manufacturer of microbiological consumables, which was acquired by Mettler Toledo in September 2017. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa (subsequently Verenium), a public company developing specialized industrial enzymes. Previously, Mr. Altig was the Chief Financial Officer of Maxim Pharmaceuticals, a public biopharmaceutical company. In addition, Mr. Altig serves as a director and Chairman of the audit committee for TearLab (formerly OccuLogix) a publicly traded eyecare technology company. He formerly served as a director of MultiCell Technologies and Optimer Pharmaceuticals, a public company, until its acquisition by Cubist Pharmaceuticals. Mr. Altig holds a BBA in Business from the University of Hawaii and is a Certified Public Accountant (inactive).